DDX41 and acute myeloid leukemia: Polprasert et al. showed that MDS/AML patients with DDX41 mutations had worse survival than patients with wildtype DDX41 in a large cohort of MDS and secondary AML patients of 1034 patients (hazard ratio, 3.5; p < 0.0001) [34].